Diclofenac Potassium is Used for relief of mild to moderate acute pain as a nonsteroidal anti-inflammatory drug. It was first introduced by Novartis Pharmaceuticals Corp in its drug Cataflam on Nov 24, 1993. Other drugs containing Diclofenac Potassium are Zipsor, Cambia. 19 different companies have introduced drugs containing Diclofenac Potassium.

Diclofenac Potassium Patents

Given below is the list of patents protecting Diclofenac Potassium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Cambia	US6974595	Pharmaceutical compositions based on Diclofenae	May 15, 2017 (Expired)	Assertio
Cambia	US7482377	Pharmaceutical compositions and methods of treatment based on diclofenac	May 15, 2017 (Expired)	Assertio
Cambia	US7759394	Diclofenac formulations and methods of use	Jun 16, 2026	Assertio
Cambia	US8097651	Diclofenac formulations and methods of use	Jun 16, 2026	Assertio
Cambia	US8927604	Diclofenac formulations and methods of use	Jun 16, 2026	Assertio
Cambia	US9827197	Diclofenac formulations and methods of use	Jun 16, 2026	Assertio
Zipsor	US6287594	Oral liquid compositions	Jan 15, 2019 (Expired)	Assertio
Zipsor	US6365180	Oral liquid compositions	Jul 15, 2019 (Expired)	Assertio
Zipsor	US7662858	Method of treating post-surgical acute pain	Feb 24, 2029	Assertio
Zipsor	US7884095	Method of treating post-surgical acute pain	Feb 24, 2029	Assertio
Zipsor	US7939518	Method of treating post-surgical acute pain	Feb 24, 2029	Assertio
Zipsor	US8110606	Method of treating post-surgical acute pain	Feb 24, 2029	Assertio
Zipsor	US8623920	Method of treating post-surgical acute pain	Feb 24, 2029	Assertio
Zipsor	US9561200	Method of treating post-surgical acute pain	Feb 24, 2029	Assertio

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Diclofenac Potassium's patents.

Latest Legal Activities on Diclofenac Potassium's Patents

Given below is the list recent legal activities going on the following patents of Diclofenac Potassium.

Event	Date	Patent/Publication
Today's Critical Events
Payment of Maintenance Fee, 12th Year, Large Entity	07 Aug, 2023	US8110606
Payment of Maintenance Fee, 12th Year, Large Entity	10 Nov, 2022	US7939518
Payment of Maintenance Fee, 12th Year, Large Entity	08 Aug, 2022	US7884095
Payment of Maintenance Fee, 12th Year, Large Entity	16 Aug, 2021	US7662858
Payment of Maintenance Fee, 4th Year, Large Entity	07 Aug, 2020	US9561200
Payment of Maintenance Fee, 8th Year, Large Entity	07 Aug, 2019	US8110606
Payment of Maintenance Fee, 8th Year, Large Entity	12 Nov, 2018	US7939518
Payment of Maintenance Fee, 8th Year, Large Entity	08 Aug, 2018	US7884095
Recordation of Patent Grant Mailed	07 Feb, 2017	US9561200
Patent Issue Date Used in PTA Calculation	07 Feb, 2017	US9561200

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳